amyloid plaque reduction

The TRAILBLAZER-ALZ 2 study (NCT04437511) demonstrated significant clinical benefits of donanemab-azbt in early symptomatic Alzheimer disease (AD). Here are the key findings:Efficacy OutcomesCognitive & Functional....

The criteria for stopping Donanemab-azbt (Kisunla) therapy are primarily based on amyloid plaque reduction and safety monitoring, as outlined in clinical guidelines and prescribing information:Primary....

Drug Information